Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.

Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Zahn MO, Wuerstlein R, Lorenz A, Bartsch R, Breitenstein U, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Valenti R, Lüftner D.

Breast Care (Basel). 2024 Feb;19(1):1-9. doi: 10.1159/000533657. Epub 2023 Oct 5.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Care
ELEANOR
2024
First-line maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma in routine care in Germany: Interim results of the prospective CARAT registry

Grünwald V. , Radkowski R. , Müller L. , Ghasemi U. , Goebell P.J. , Deger S. , Andres-Pons A. , Lennartz C. , Jänicke M. , Staehler M. , Gratzke C. , Potthoff K.; 2024

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARAT
2024
Treatment reality and outcomes of patients with intermediate, locally advanced or metastatic hepatocellular cancer – Results from the prospective national intersectoral cohort study JADE

Berg T, Dörfel S, Jordan F, Schultheiß M, Schröder J, Benkelmann R, Sergeev P, Heinzow H, Lamberti C, Weniger S, Siebenbach HU, Weinberg F, Jänicke M, Pereira PL, Hofmann WP, Potthoff K, Galle PR, Thimme R, 2024.

Abstract

Indikation: Hepatocellular Carcinoma, Hepatozelluläres Karzinom, Leberkrebs, Liver Cancer / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
JADE
2024
Real-world effectiveness in the total population and in specific subgroups of treatment with palbociclib + endocrine therapy in HR+/HER2- Advanced Breast Cancer (ABC) patients: Interim Results of the PERFORM study

Korell M., Pfeiler G., Radosa J., Decker T., Deryal M., Fietz T., Köhler A., Schöttker B., Wilke J., Knoblich J., Petersen V., Dietrich M., Gabrysiak T., Breitbach A., Adams A., Seidel S., Glasstetter M., Serrer L., Lux M.P., Bartsch R., 2024

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal:
PERFORM
2024
Centralized vs. decentralized testing for PD-L1 and HER2 in patients with metastatic gastric and esophageal cancer – Results from the German research platform SAPHIR

Lordick, F., Bläker, H., Dechow, T., Binninger, A., Ringwald, K., de Buhr, R., von der Heyde, E., Zahn, M.-O., Nusch, A., Dörfel, S., Schulz, H., Lorenzen, S., Reinacher-Schick, A., Haffner I., Jänicke, M., Potthoff, K., 2024. Oncol Res Treat, DGHO-Jahrestagung (Basel) https://doi.org/10.1159/000540557

Abstract

Indikation: Esophageal Cancer, Gastric Cancer, Magenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
SAPHIR
2024
Patients with multiple myeloma – What happens in second line after first-line refractory to daratumumab? Data from the German MYRIAM registry

Nusch, A., Burkhard-Meier, U., Jacobasch, L., Linde, H., Uhlig, J., Welslau, M., Tech, S., Medinger, T., Jänicke, M., Dechow, T., Einsele, H., Engelhardt, M., Knauf, W., Marschner, P., 2024
Oncol Res Treat (2024) 47 (Suppl. 2) (P741): p. 241

Download

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYRIAM
2024
Real-world data on systemic treatment and biomarker testing in patients with advanced or metastatic endometrial cancer: results from the German registry platform SMARAGD

Gratzke K., Decker T., Juhasz-Böss I., Zaiss M., Papathemelis T., Flade F., Haus A., Jaenicke M., Winter S., Georganoudis N., Marschner N., Stickeler E., Welt A., Watermann D. , Wöckel A.; 2024, Posternumber P349

Download

Indikation: Endometrial Cancer, Endometriumkarzinom / Veranstaltung: DGHO / Journal:
SMARAGD
2024
Real world data on pathological complete remission after neoadjuvant therapy with or without anthracyclines in patients with HER2-positive breast cancer – data from the registry platform OPAL

Zahn M.-O. , Decker T. , Stickeler E. , Zaiss M. , Fietz T. , Nusch A. , Peters N. , Wende C. , Beurer B. , Jänicke M. , Lennartz C. , Kruggel L. , Harbeck N. , Wöckel A. , Thill M. , Welt A. , Marschner N. , Gratzke K., 2024

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal:
OPAL
2024
Real-world data on patients’ adherence to prescribed treatment schedules with carfilzomib and dexamethasone (Kd), or in combination with lenalidomide (KRd) or daratumumab (KdD) in patients with multiple myeloma – Results from the interim analysis 3 of CARO

Knauf, Wolfgang; Uhlig, Jens; Von der Heyde, Eyck; Losem, Christoph ; Ammon, Andreas; Nusch, Arnd; Schlag Rudolf; Schulz, Holger; Behlendorf, Timo; Siebenbach, Hans Ulrich; Serrer, Laura; Woerner, Sandra; Potthoff, Karin; 2024

Download

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: DGHO / Journal:
CARO
2024
SEATTLE – Real-world data on quality of life (QoL) and safety of selinexor in combination with bortezomib and dexamethasone (SVd) in patients with relapsed/refractory multiple myeloma (R/RMM)

Dechow T., Pelz H., Zaiss M., Wilop S., Nusch A., Schulz H., Von der Heyde E. Ringwald K., Kummer D., Woerner S.M., Marschner N., Marschner P.; 2024

Download

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: DGHO / Journal:
SEATTLE
2024